Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.03M Sell
22,167
-126
-0.6% -$43.1K 1.27% 22
2026
Q1
$7.84M Buy
22,293
+44
+0.2% +$15.7K 1.35% 20
2025
Q4
$7.28M Sell
22,249
-1,117
-5% -$354K 1.25% 24
2025
Q3
$6.09M Buy
23,366
+1,289
+6% +$374K 1.19% 27
2025
Q2
$6.16M Buy
22,077
+100
+0.5% +$28.3K 1.09% 33
2025
Q1
$6.85M Sell
21,977
-1,389
-6% -$410K 1.3% 20
2024
Q4
$6.09M Buy
23,366
+954
+4% +$283K 1.31% 23
2024
Q3
$7.22M Buy
22,412
+1,583
+8% +$518K 1.42% 19
2024
Q2
$6.51M Sell
20,829
-675
-3% -$198K 1.38% 21
2024
Q1
$6.11M Sell
21,504
-888
-4% -$260K 1.3% 27
2023
Q4
$6.45M Sell
22,392
-165
-0.7% -$45K 1.48% 21
2023
Q3
$6.06M Sell
22,557
-72
-0.3% -$18K 1.52% 20
2023
Q2
$5.02M Buy
22,629
+785
+4% +$182K 1.22% 28
2023
Q1
$5.28M Buy
21,844
+1,196
+6% +$294K 1.33% 26
2022
Q4
$5.42M Buy
20,648
+2,415
+13% +$647K 1.4% 24
2022
Q3
$4.11M Buy
18,233
+454
+3% +$110K 1.15% 29
2022
Q2
$4.33M Buy
17,779
+788
+5% +$193K 1.2% 25
2022
Q1
$4.11M Buy
16,991
+755
+5% +$173K 0.91% 48
2021
Q4
$3.65M Buy
16,236
+1,122
+7% +$237K 0.77% 58
2021
Q3
$3.21M Buy
15,114
+531
+4% +$122K 0.76% 59
2021
Q2
$3.52M Buy
14,583
+754
+5% +$185K 0.81% 59
2021
Q1
$3.44M Buy
13,829
+1,017
+8% +$243K 0.85% 53
2020
Q4
$2.95M Buy
+12,812
New +$2.95M 0.82% 55

Other funds holding AMGN

Kesler Norman & Wride's AMGN Position: Q2 2026 in Review

Kesler Norman & Wride reduced its Amgen (AMGN) stake by 0.57% in Q2 2026, selling an estimated $43.1K and leaving 22,167 shares worth $8.03M. The position accounts for 1.27% of the portfolio, ranked #22.

Kesler Norman & Wride first reported a position in AMGN in Q4 2020 and has held it in 23 quarters since. 1,262 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Kesler Norman & Wride held 22,167 shares of Amgen worth $8.03M as of Q2 2026.
  • Kesler Norman & Wride sold 126 Amgen shares in Q2 2026, an estimated $43.1K.
  • Amgen made up 1.27% of Kesler Norman & Wride's portfolio in Q2 2026, its #22 holding.
  • Kesler Norman & Wride first reported a position in Amgen in Q4 2020 and has held it in 23 quarters since.
  • 1,262 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Kesler Norman & Wride's 13F filing for Q2 2026, filed 23 Jul 2026.